84
Participants
Start Date
December 7, 2017
Primary Completion Date
July 22, 2022
Study Completion Date
July 22, 2022
Anastrozole
"Anastrozole is an aromatase inhibitor indicated for:~* adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer~* first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer~* treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
Placebo Oral Tablet
matching placebo tablet
University of Pennsylvania, Philadelphia
Johns Hopkins University, Baltimore
Vanderbilt University, Nashville
Washington University, St Louis
University of Colorado - Denver, Aurora
Stanford University, Stanford
Rhode Island Hospital, East Providence
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Johns Hopkins University
OTHER
University of Colorado, Denver
OTHER
Rhode Island Hospital
OTHER
Stanford University
OTHER
Vanderbilt University
OTHER
Washington University School of Medicine
OTHER
University of Pennsylvania
OTHER